FY2025 EPS Estimates for Genmab A/S Reduced by William Blair

Genmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at William Blair dropped their FY2025 earnings per share estimates for shares of Genmab A/S in a research report issued on Monday, April 14th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of $1.29 for the year, down from their prior forecast of $1.66. William Blair has a "Outperform" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S's FY2026 earnings at $1.86 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Other equities research analysts also recently issued research reports about the stock. Truist Financial reduced their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, HC Wainwright restated a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Stock Up 0.4 %

GMAB traded up $0.09 during trading on Thursday, reaching $20.16. 873,831 shares of the company's stock were exchanged, compared to its average volume of 1,542,853. The company has a market capitalization of $13.34 billion, a P/E ratio of 11.58, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41. The business has a 50 day moving average price of $20.55 and a 200 day moving average price of $21.11.

Institutional Trading of Genmab A/S

A number of large investors have recently added to or reduced their stakes in the company. Deep Track Capital LP acquired a new position in shares of Genmab A/S in the fourth quarter valued at $41,740,000. Renaissance Technologies LLC raised its holdings in Genmab A/S by 7.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after acquiring an additional 139,722 shares during the period. Two Sigma Investments LP lifted its position in Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after acquiring an additional 938,455 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after acquiring an additional 1,038,400 shares during the period. Finally, First Trust Advisors LP grew its position in shares of Genmab A/S by 18.0% in the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock valued at $34,316,000 after purchasing an additional 251,241 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.